

Brand Name: EUREKAVONE INJECTION

Composition: Edaravone Injection IP

Dosage Form: INJECTION

Category: Neuroprotective Agent / Free Radical Scavenger

Packaging Type: VIAL +Try pack

Packaging: 20 ML

Brief Product Introduction:

EUREKAVONE INJECTION is a sterile, antioxidant-based neuroprotective formulation developed by **AstraEureka Pharmaceutical**, a trusted **manufacturer of composition-based injectable therapies**. Each ml contains **1.5 mg of Edaravone**, a potent free radical scavenger that reduces oxidative stress in neuronal tissues. It is indicated primarily in the management of **acute ischemic stroke** and **amyotrophic lateral sclerosis (ALS)**. By inhibiting lipid peroxidation and oxidative neuronal damage, EUREKAVONE helps preserve motor function and improve neurological outcomes. Administered via IV infusion under medical supervision, it plays a crucial role in early neuroprotection post-stroke. The formulation is stable, well tolerated, and suited for use in hospital settings, ICUs, and neurology departments for acute care.

Composition:

Each 1 ml Contains:

- Edaravone.....1.5 mg
- Water for Injection IP.....Q.S.

Key Ingredients

- **Edaravone (1.5 mg/ml):**
 - A synthetic antioxidant that neutralizes free radicals
 - Helps protect neurons from ischemia-reperfusion injury
- **Water for Injection IP:**
 - Sterile vehicle for parenteral administration

Key Benefits:

1. Reduces oxidative stress in brain tissue
2. Helps limit neuronal damage during acute stroke
3. Improves motor function in ALS patients
4. Enhances neurological recovery when given early
5. Suitable for hospital-based neurocritical care

Indications:

1. Acute ischemic stroke (within 24–48 hours of onset)
2. Amyotrophic lateral sclerosis (ALS)
3. Neuroinflammatory conditions with oxidative stress
4. Supportive therapy in traumatic brain injury (as advised)
5. Neuroprotection in certain intensive care situations

Directions for Use:

1. For **intravenous infusion only**
2. Dilute in appropriate infusion fluid as advised by healthcare professional
3. Administer over **30–60 minutes**
4. Use under strict medical supervision
5. Do not administer as IV push or bolus

Dosage and Administration:

1. **For Stroke:**
 - 30 mg diluted in 100 ml normal saline
 - Administered twice daily via IV infusion over 30–60 minutes
 - Continue for 14 consecutive days, then stop
2. **For ALS:**
 - Dose and duration may vary per guideline (typically cyclic dosing)
3. Dose adjustments may be required based on renal function

Mechanism of Action:

- Edaravone acts as a **free radical scavenger**, specifically targeting hydroxyl radicals and peroxynitrite. These reactive oxygen species are elevated during ischemic stroke or neurodegenerative processes, causing lipid peroxidation and cellular injury.
- By neutralizing these radicals, Edaravone prevents damage to vascular endothelium, neurons, and supporting glial cells, thereby reducing infarct size and preserving brain tissue.
- In ALS, it slows the progression of functional decline by minimizing oxidative damage to motor neurons.

Safety Information:

1. Monitor renal and hepatic function before and during therapy
2. Administer in a clinical setting with resuscitative equipment nearby
3. Avoid rapid infusion to prevent hypotension
4. Use sterile technique for preparation and administration

5. Discard unused portion after opening

Contraindications:

1. Known hypersensitivity to Eदारavone or formulation components
2. Severe renal impairment or dialysis patients
3. Active bleeding disorders
4. Pregnancy and lactation (unless clearly needed and prescribed)

Side Effects:

1. Rash, pruritus, or injection site reactions
2. Headache, dizziness
3. Nausea or loss of appetite
4. Elevated liver enzymes (transient)
5. Rare: Hypersensitivity, anaphylactoid reactions

Important Notice:

- EUREKAVONE INJECTION is a **prescription-only hospital-use product**
- Early administration post-stroke onset is critical for efficacy
- Not a substitute for thrombolysis or mechanical thrombectomy
- Must be administered by trained healthcare personnel

Storage Condition:

1. Store at temperature below 25°C
2. Protect from light and freezing
3. Keep vial in original packaging until use
4. Use reconstituted/diluted solution immediately

Packing Information:

- Supplied in **20 ml** vial + Try with outer box